Antituberculosis	antituberculosis	O	O	OTHERS	I
therapy-induced	therapy-induced	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
liver	liver	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
:	:	O	O	O	O
magnitude	magnitude	O	O	O	O
,	,	O	O	O	O
profile	profile	O	O	O	O
,	,	O	O	O	O
prognosis	prognosis	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
predictors	predictors	O	O	O	O
of	of	O	O	O	O
outcome	outcome	O	O	O	O
.	.	O	O	O	O

Antituberculosis	antituberculosis	O	O	OTHERS	I
therapy	therapy	O	O	O	O
(ATT)-associated	(att)-associated	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
liver	liver	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
(	(	O	O	O	O
ATT-ALF	att-alf	O	O	O	O
)	)	O	O	O	O
is	is	O	O	O	O
the	the	O	O	O	O
commonest	commonest	O	O	O	O
drug-induced	drug-induced	O	O	O	O
ALF	alf	O	DISEASE	OTHERS	I
in	in	O	O	O	O
South	south	O	O	O	O
Asia	asia	O	O	O	O
.	.	O	O	O	O

Prospective	prospective	O	O	O	O
studies	studies	O	O	O	O
on	on	O	O	O	O
ATT-ALF	att-alf	O	O	O	O
are	are	O	O	O	O
lacking	lacking	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
current	current	O	O	O	O
study	study	O	O	O	O
prospectively	prospectively	O	O	O	O
evaluated	evaluated	O	O	O	O
the	the	O	O	O	O
magnitude	magnitude	O	O	O	O
,	,	O	O	O	O
clinical	clinical	O	O	O	O
course	course	O	O	O	O
,	,	O	O	O	O
outcome	outcome	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
prognostic	prognostic	O	O	O	O
factors	factors	O	O	O	O
in	in	O	O	O	O
ATT-ALF	att-alf	O	O	O	O
.	.	O	O	O	O

From	from	O	O	O	O
January	january	O	O	O	O
1986	1986	O	O	O	O
to	to	O	O	O	O
January	january	O	O	O	O
2009	2009	O	O	O	O
,	,	O	O	O	O
1223	1223	O	O	O	O
consecutive	consecutive	O	O	O	O
ALF	alf	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
:	:	O	O	O	O
ATT	att	O	O	O	O
alone	alone	O	O	O	O
was	was	O	O	O	O
the	the	O	O	O	O
cause	cause	O	O	O	O
in	in	O	O	O	O
70	70	O	O	O	O
(	(	O	O	O	O
5.7	5.7	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Another	another	O	O	O	O
15	15	O	O	O	O
(	(	O	O	O	O
1.2	1.2	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
ATT	att	O	O	O	O
and	and	O	O	O	O
simultaneous	simultaneous	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
virus	virus	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
44	44	O	O	O	O
(	(	O	O	O	O
62.8	62.8	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
ATT	att	O	O	O	O
was	was	O	O	O	O
prescribed	prescribed	O	O	O	O
empirically	empirically	O	O	O	O
without	without	O	O	O	O
definitive	definitive	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
tuberculosis	tuberculosis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

ATT-ALF	att-alf	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
younger	younger	O	O	O	O
(	(	O	O	O	O
32.87	32.87	O	O	O	O
[	[	O	O	O	O
+	+	O	O	O	O
/-15.8	/-15.8	O	O	O	O
]	]	O	O	O	O
years	years	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
49	49	O	O	O	O
(	(	O	O	O	O
70	70	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
them	them	O	O	O	O
were	were	O	O	O	O
women	women	O	O	O	O
.	.	O	O	O	O

Most	most	O	O	O	O
had	had	O	O	O	O
hyperacute	hyperacute	O	O	O	O
presentation	presentation	O	O	O	O
;	;	O	O	O	O
the	the	O	O	O	O
median	median	O	O	O	O
icterus	icterus	O	O	OTHERS	I
encephalopathy	encephalopathy	O	DISEASE	OTHERS	I
interval	interval	O	O	O	O
was	was	O	O	O	O
4.5	4.5	O	O	O	O
(	(	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
30	30	O	O	O	O
)	)	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
median	median	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
ATT	att	O	O	O	O
before	before	O	O	O	O
ALF	alf	O	DISEASE	OTHERS	I
was	was	O	O	O	O
30	30	O	O	O	O
(	(	O	O	O	O
7	7	O	O	O	O
-	-	O	O	O	O
350	350	O	O	O	O
)	)	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

At	at	O	O	O	O
presentation	presentation	O	O	O	O
,	,	O	O	O	O
advanced	advanced	O	O	O	O
encephalopathy	encephalopathy	O	DISEASE	OTHERS	I
and	and	O	O	O	O
cerebral	cerebral	O	DISEASE	OTHERS	I
edema	edema	O	DISEASE	OTHERS	I
were	were	O	O	O	O
present	present	O	O	O	O
in	in	O	O	O	O
51	51	O	O	O	O
(	(	O	O	O	O
76	76	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
29	29	O	O	O	O
(	(	O	O	O	O
41.4	41.4	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

Gastrointestinal	gastrointestinal	O	O	OTHERS	I
bleed	bleed	O	O	OTHERS	I
,	,	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
,	,	O	O	O	O
infection	infection	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
were	were	O	O	O	O
documented	documented	O	O	O	O
in	in	O	O	O	O
seven	seven	O	O	O	O
(	(	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
five	five	O	O	O	O
(	(	O	O	O	O
7.1	7.1	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
26	26	O	O	O	O
(	(	O	O	O	O
37.1	37.1	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
seven	seven	O	O	O	O
(	(	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

Compared	compared	O	O	O	O
with	with	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
E	e	O	DISEASE	OTHERS	I
virus	virus	O	O	O	O
(	(	O	O	O	O
HEV	hev	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
non-A	non-a	O	O	O	O
non-E-induced	non-e-induced	O	O	O	O
ALF	alf	O	DISEASE	OTHERS	I
,	,	O	O	O	O
ATT-ALF	att-alf	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
nearly	nearly	O	O	O	O
similar	similar	O	O	O	O
presentations	presentations	O	O	O	O
except	except	O	O	O	O
for	for	O	O	O	O
older	older	O	O	O	O
age	age	O	O	O	O
and	and	O	O	O	O
less	less	O	O	O	O
elevation	elevation	O	O	O	O
of	of	O	O	O	O
liver	liver	O	O	O	O
enzymes	enzymes	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
mortality	mortality	O	O	O	O
rate	rate	O	O	O	O
among	among	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
ATT-ALF	att-alf	O	O	O	O
was	was	O	O	O	O
high	high	O	O	O	O
(	(	O	O	O	O
67.1	67.1	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
47	47	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
only	only	O	O	O	O
23	23	O	O	O	O
(	(	O	O	O	O
32.9	32.9	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
patients	patients	O	O	O	O
recovered	recovered	O	O	O	O
with	with	O	O	O	O
medical	medical	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
multivariate	multivariate	O	O	O	O
analysis	analysis	O	O	O	O
,	,	O	O	O	O
three	three	O	O	O	O
factors	factors	O	O	O	O
independently	independently	O	O	O	O
predicted	predicted	O	O	O	O
mortality	mortality	O	O	O	O
:	:	O	O	O	O
serum	serum	O	O	O	O
bilirubin	bilirubin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
>	>	O	O	O	O
or=10.8	or=10.8	O	O	O	O
mg/dL	mg/dl	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
prothrombin	prothrombin	O	O	O	O
time	time	O	O	O	O
(	(	O	O	O	O
PT	pt	O	O	O	O
)	)	O	O	O	O
prolongation	prolongation	O	O	O	O
(	(	O	O	O	O
>	>	O	O	O	O
or=26	or=26	O	O	O	O
seconds	seconds	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
grade	grade	O	O	O	O
III/IV	iii/iv	O	O	O	O
encephalopathy	encephalopathy	O	DISEASE	OTHERS	I
at	at	O	O	O	O
presentation	presentation	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
ATT-ALF	att-alf	O	O	O	O
constituted	constituted	O	O	O	O
5.7	5.7	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
ALF	alf	O	DISEASE	OTHERS	I
at	at	O	O	O	O
our	our	O	O	O	O
center	center	O	O	O	O
and	and	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
high	high	O	O	O	O
mortality	mortality	O	O	O	O
rate	rate	O	O	O	O
.	.	O	O	O	O

Because	because	O	O	O	O
the	the	O	O	O	O
mortality	mortality	O	O	O	O
rate	rate	O	O	O	O
is	is	O	O	O	O
so	so	O	O	O	O
high	high	O	O	O	O
,	,	O	O	O	O
determining	determining	O	O	O	O
which	which	O	O	O	O
factors	factors	O	O	O	O
are	are	O	O	O	O
predictors	predictors	O	O	O	O
is	is	O	O	O	O
less	less	O	O	O	O
important	important	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
high	high	O	O	O	O
proportion	proportion	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
consumed	consumed	O	O	O	O
ATT	att	O	O	O	O
empirically	empirically	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
could	could	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
prevented	prevented	O	O	O	O
.	.	O	O	O	O

